Drug Trial Radar · NCT04429087
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
306
Actual
Start
Jul 29, 2020
Primary completion
Aug 31, 2026
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig and the best treatment schedule that people can tolerate. Obrixtamig is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, obrixtamig is given to people for the first time. Interim clinical data are available for obrixtamig. Participants get obrixtamig either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
Conditions
- Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Interventions
Obrixtamig - parenteral 1Drug
Obrixtamig - parenteral 1
Obrixtamig - parenteral 2Drug
Obrixtamig - parenteral 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm 1 and Arm 2: Maximum tolerated dose (MTD)Time frame: up to 36 months
- Arm 1 and Arm 2: Number of patients with DLTs in the MTD evaluation periodTime frame: up to 36 months
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Winship Cancer Institute
Atlanta, Georgia
University of Maryland School of Medicine
Baltimore, Maryland
Washington University School of Medicine
St Louis, Missouri
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Universitätsklinikum Köln (AöR)
Cologne, Germany
Technische Universität Dresden
Dresden, Germany
Universitätsklinikum Würzburg AÖR
Würzburg, Germany
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Hospital del Mar
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.